GW Pharmaceuticals PLC- Sets New 52-Week High Following Analyst Upgrade (GWPH)
Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) hit a new 52-week high during mid-day trading on Monday after Piper Jaffray raised their price target on the stock from $97.00 to $147.00, Stock Ratings News reports. Piper Jaffray currently has an overweight rating on the stock. GW Pharmaceuticals PLC- traded as high as $108.89 and last traded at $106.80, with a volume of 2,900,987 shares traded. The stock had previously closed at $96.14.
A number of other firms have also recently commented on GWPH. Analysts at Citigroup Inc. cut their price target on shares of GW Pharmaceuticals PLC- from $97.00 to $86.00 in a research note on Monday. Separately, analysts at Morgan Stanley reiterated an “overweight” rating on shares of GW Pharmaceuticals PLC- in a research note on Friday, May 16th. They now have a $103.00 price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of GW Pharmaceuticals PLC- from $79.00 to $90.00 in a research note on Thursday, May 8th. They now have an “outperform” rating on the stock. Six investment analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $90.75.
The stock has a 50-day moving average of $75.90 and a 200-day moving average of $61.02. The company’s market cap is $1.860 billion.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.04) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.48) by $0.44. The company had revenue of $12.55 million for the quarter, compared to the consensus estimate of $12.48 million. GW Pharmaceuticals PLC-’s revenue was up 63.6% compared to the same quarter last year. On average, analysts predict that GW Pharmaceuticals PLC- will post $-2.07 earnings per share for the current fiscal year.
GW Pharmaceuticals plc is a United Kingdom-based company. The Company is engaged in the research, development and commercialization of a range of cannabinoid prescription medicines to meet patient needs in a range of medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.